BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Acanfora D, Scicchitano P, Acanfora C, Maestri R, Goglia F, Incalzi RA, Bortone AS, Ciccone MM, Uguccioni M, Casucci G. Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis. Clin Drug Investig 2020;40:493-501. [DOI: 10.1007/s40261-020-00908-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Rex DAB, Arun Kumar ST, Modi PK, Keshava Prasad TS. Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target? OMICS 2021;25:408-16. [PMID: 34191617 DOI: 10.1089/omi.2021.0080] [Reference Citation Analysis]
2 Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother 2020;6:135-6. [PMID: 32282032 DOI: 10.1093/ehjcvp/pvaa028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
3 Acanfora D, Nolano M, Acanfora C, Colella C, Provitera V, Caporaso G, Rodolico GR, Bortone AS, Galasso G, Casucci G. Impaired Vagal Activity in Long-COVID-19 Patients. Viruses 2022;14:1035. [DOI: 10.3390/v14051035] [Reference Citation Analysis]
4 Thornby KA, Maksutovic NM. A Systematic Review on the Use of Sacubitril/Valsartan Initiated Prior to Discharge in Hospitalized Patients With Heart Failure. Ann Pharmacother 2021;55:378-89. [PMID: 32698597 DOI: 10.1177/1060028020943940] [Reference Citation Analysis]
5 Casucci G, Acanfora D, Incalzi RA. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs Aging 2020;37:779-85. [PMID: 33084001 DOI: 10.1007/s40266-020-00808-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
6 Chalikias G, Tziakas D. Angiotensin Receptor Neprilysin Inhibitors—2019 Update. Cardiovasc Drugs Ther 2020;34:707-22. [DOI: 10.1007/s10557-020-07015-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mohyeldin M, Tavares LB, Boorenie M, Abureesh D, Ejaz S, Durrani L, Khan S. Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review. Cureus 2021;13:e18740. [PMID: 34659932 DOI: 10.7759/cureus.18740] [Reference Citation Analysis]
8 Manolis AS, Manolis TA, Manolis AA, Melita H. The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. J Cardiovasc Pharmacol 2020;76:397-406. [PMID: 32769760 DOI: 10.1097/FJC.0000000000000894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
9 Corrado E, Dattilo G, Coppola G, Morabito C, Bonni E, Zappia L, Novo G, de Gregorio C. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. Eur J Clin Pharmacol 2021. [PMID: 34554274 DOI: 10.1007/s00228-021-03210-0] [Reference Citation Analysis]
10 Bolla GB, Fedele A, Faggiano A, Sala C, Santangelo G, Carugo S. Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovasc Disord 2022;22:217. [PMID: 35562650 DOI: 10.1186/s12872-022-02647-0] [Reference Citation Analysis]